Clinical challenges in the pharmacologic management of agitation

Primary Psychiatry

Volumn 17, Issue 8, 2010, Pages 46-52

  Ng, Anthony T ^a   Zeller, Scott L ^b   Rhoades, Robert W ^c  

^a Acadia Hospital   (United States)

^b ALAMEDA COUNTY MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FLUOXETINE; FLUVOXAMINE; GLUCOCORTICOID; HALOPERIDOL; ILLICIT DRUG; LORAZEPAM; MACROLIDE; NEUROLEPTIC AGENT; OLANZAPINE; PHENOBARBITAL; PHENYTOIN; PRESCRIPTION DRUG; QUETIAPINE; QUINIDINE; RIFAMPICIN; RISPERIDONE; SERTRALINE; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE;

AGITATION; AKATHISIA; ARTICLE; BRADYCARDIA; COGNITIVE DEFECT; DISEASE ASSOCIATION; DIZZINESS; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG ALCOHOL INTERACTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DYSPHORIA; DYSTONIA; EMERGENCY CARE; ENZYME INHIBITION; EXTRAPYRAMIDAL SYNDROME; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HEART DISEASE; HUMAN; HYPERTENSION; LONG TERM CARE; MENTAL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEEDLESTICK INJURY; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PERSUASIVE COMMUNICATION; QT PROLONGATION; RESTLESSNESS; RISK ASSESSMENT; SCHIZOPHRENIA; SEDATION; SOMNOLENCE;

EID: 77956193101     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Zimbroff DL. Pharmacological control of acute agitation: focus on intramuscular preparations. CNS Drugs. 2008;22(3):199-212.
2. Citrome L. Atypical antipsychotics for acute agitation. New intramuscular options offer advantages. Postgrad Med. 2002;112(6):85-88, 94-96.
3. Zimbroff DL, Allen MH, Battaglia J, et al. Best clinical practice with ziprasidone IM: update after 2 years of experience. CNS Spectr. 2005;10(9):1-15.
4. Allen MH, Currier GW. Use of restraints and pharmacotherapy in academic psychiatric emergency services. Gen Hosp Psychiatry. 2004;26(1):42-49.
5. Marco CA, Vaughan J. Emergency management of agitation in schizophrenia. Am J Emerg Med. 2005;23(6):767-776.
6. Huf G, Alexander J, Allen MH. Haloperidol plus promethazine for psychosis induced aggression. Cochrane Database Syst Rev. 2005;(1):CD005146.
7. D'Amore J, Hung O, Chiang W, Goldfrank L. The epidemiology of the homeless population and its impact on an urban emergency department. Acad Emerg Med. 2001;8(11):1051-1055.
8. Zun LS, Downey LV. Level of agitation of psychiatric patients presenting to an emergency department. Prim Care Companion J Clin Psychiatry. 2008;10(2):108-113.
9. Chou KR, Lu RB, Mao WC. Factors relevant to patient assaultive behavior and assault in acute inpatient psychiatric units in Taiwan. Arch Psychiatr Nurs. 2002;16(4):187-195.
10. Sachs GS. A review of agitation in mental illness: burden of illness and underlying pathology. J Clin Psychiatry. 2006;67(suppl 10):5-12.
11. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63(12):1121-1128.
12. Amore M, Menchetti M, Tonti C, et al. Predictors of violent behavior among acute psychiatric patients: clinical study. Psychiatry Clin Neurosci. 2008;62(3):247-255.
13. Palmstierna T, Huitfeldt B, Wistedt B. The relationship of crowding and aggressive behavior on a psychiatric intensive care unit. Hosp Community Psychiatry. 1991;42(12):1237-1240.
14. Zeller S, Bruch SM. Agitation I: overview of agitation and violence. In: Glick RL, Berlin AB, Fishkind AB, Zeller SL, eds. Emergency Psychiatry: Principles and Practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:117-124.
15. Almvik R, Woods P, Rasmussen K. The Brøset Violence Checklist. Sensitivity, specificity, and interrater reliability. J Interpersonal Violence. 2000;15(12):1284-1296.
16. Douglas KS, Guy LS, Weir J. HCR-20 violence risk assessment scheme: overview and annotated bibliography. 2006. Available at: www.sfu.ca/psyc/faculty/hart/HCR-20%20Annotated%20Bibliograph,%202006.pdf. Accessed July 14, 2010.
17. McNiel DE, Binder RL. Screening for risk of inpatient violence. Law Human Behav. 1994;18:579-586.
18. Downey LV, Zun LS, Gonzales SJ. Frequency of alternative to restraints and seclusion and uses of agitation reduction techniques in the emergency department. Gen Hosp Psychiatry. 2007;29(6):470-474.
19. Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP; Expert Consensus Panel for Behavioral Emergencies. The expert consensus guideline series. Treatment of behavioral emergencies. Postgrad Med. 2001(Spec no):1-88.
20. American Psychiatric Association Task Force on the Psychiatric Uses of Seclusion and Restraint. Seclusion and Restraint: The Psychiatric Uses. Washington, DC: American Psychiatric Association; 1985.
21. Fernandes CM, Bouthillette F, Raboud JM, et al. Violence in the emergency department: a survey of health care workers. CMAJ. 1999;161(1):1245-1248.
22. Battaglia J. Pharmacological management of acute agitation. Drugs. 2005;65(9):1207-1222.
23. Battaglia J, Robinson DG, Citrome L. The treatment of acute agitation in schizophrenia. CNS Spectr. 2007;12(8Suppl 11):1-16.
24. Jaber S, Chanques G, Altairac C, et al. A prospective study of agitation in a medical-surgical ICU: incidence, risk factors, and outcomes. Chest. 2005;128:2749-2757.
25. Martel M, Sterzinger A, Miner J, Clinton J, Biros M. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. Acad Emerg Med. 2005;12(12):1167-1172.
26. Daniel DG. Recent developments in pharmacotherapy for the acutely psychotic patient. J Emerg Nurs. 2002;28 (6 Suppl):S12-S20.
27. Tueth MJ. Diagnosing psychiatric emergencies in the elderly. Am J Emerg Med. 1994;12:364-369.
28. Zimbroff DL, Marcus RN, Manos G, et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol. 2007;27(2):171-176.
29. Miczek KA, Fish EW, De Bold HF, et al. Social and neural determinants of aggressive behavior: pharmacotherapeutic targets at serotonin, dopamine and gamma-aminobutyric acid systems. Psychopharmacology (Berl). 2002;163(3-4):434-458.
30. Kavoussi R, Armstead P, Coccaro E. The neurobiology of impulsive aggression. Psychiatr Clin North Am. 1997;20(2):395-403.
31. Van Winkle E. The toxic mind: the biology of mental illness and violence. Med Hypotheses. 2000;55(4):356-368.
32. Lindenmayer JP. The pathophysiology of agitation. J Clin Psychiatry. 2000;61(suppl 14):5-10.
33. Knott JC, Isbister GK. Sedation of agitated patients in the emergency department. Emerg Med Australas. 2008;20(2):97-100.
34. Allen MH. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry. 2000;61(suppl 14):11-20.
35. Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J. 2003;20(4):339-346.
36. Citrome L. Agitation III: pharmacologic treatment of agitation. In: Glick RL, Berlin AB, Fishkind AB, Zeller SL, eds. Emergency Psychiatry: Principles and Practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:137-147.
37. Lukens TW, Wolf SJ, Edlow JA, et al. Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department. Ann Emerg Med. 2006;47(1):79-99.
38. Nassisi D, Korc B, Hahn S, Bruns J Jr, Jagoda A. The evaluation and management of the acutely agitated elderly patient. Mt Sinai J Med. 2006;73(7):976-984.
39. Stapczynski JS. AllBusiness. Agitation: what every emergency physician should know. Available at: www.allbusiness.com/print/12877293-1-22eeq.html. Accessed June 21, 2010.
40. Fishkind A. Agitation II: De-escalation of the Aggressive Patient and Avoiding Coercion. In: Glick RL, Berlin AB, Fishkind AB, Zeller SL, eds. Emergency Psychiatry: Principles and Practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:125-136.
41. Citrome L. Current treatments of agitation and aggression. 2002. Available at: http://cme.medscape.com/viewarticle/433701_print. Accessed June 21, 2010.
42. Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP; Expert Consensus Panel for Behavioral Emergencies 2005. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract. 2005;11(suppl 1):5-108.
43. National Institute for Health and Clinical Excellence. Violence: The Short-term Management of Disturbed/violent Behaviour in In-patient Psychiatric Settings and Emergency Departments. London: Royal College of Nursing; 2006.
44. Huf G, Coutinho ES, Adams CE. TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry. 2002;2:11.
45. Foster S, Kessel J, Berman ME, Simpson GM. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol. 1997;12(3):175-179
46. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry. 2001;62(3):153-157.
47. Milton GV, Jann MW. Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs. Clin Pharmacokinet. 1995;28(6):494-504.
48. Zeller SL, Rhoades RW. Systematic reviews of assessment measures and pharmacologic treatments for agitation. Clin Ther. 2010;32(3):403-425.
49. Tveita T, Thoner J, Klepstad P, Dale O, Jystad A, Borchgrevink PC. A controlled comparison between single doses of intravenous and intramuscular morphine with respect to analgesic effects and patient safety. Acta Anaesthesiol Scand. 2008;52(7):920-925.
50. Zhu M, Burman WJ, Jaresko GS, Berning SE, Jelliffe RW, Peloquin CA. Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. Pharmacotherapy. 2001;21(9):1037-1045.
51. Nobay F, Simon BC, Levitt MA, Dresden GM. A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients. Acad Emerg Med. 2004;11(7):744-749.
52. Levenson JL. Textbook of Psychosomatic Medicine. Arlington, VA: American Psychiatric Publishing. 2005.
53. Hilt RJ, Woodward TA. Agitation treatment for pediatric emergency patients. J Am Acad Child Adolesc Psychiatry. 2008;47(2):132-138.
54. Fisman DN, Harris AD, Sorock GS, Mittleman MA. Sharps-related injuries in health care workers: a case-crossover study. Am J Med. 2003;114(8):688-694.
55. Zimbroff DL. Clinical management of agitation. 2003. Available at: http://cme.medscape.com/viewarticle/451806. Accessed June 21, 2010.
56. Allen MH, Carpenter D, Sheets JL, Miccio S, Ross R. What do consumers say they want and need during a psychiatric emergency? J Psychiatr Pract. 2003;9(1):39-58.
57. Murphy MC. The agitated psychotic patient: guidelines to ensure staff and patient safety. J Am Psychiat Nur Assoc. 2002;8(suppl 4):S2-S8.
58. Bartkó G. New formulations of olanzapine in the treatment of acute agitation. Neuropsychopharmacol Hung. 2006;8(4):171-178.
59. Kinon BJ, Ahl J, Rotelli MD, McMullen E. Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. Am J Emerg Med. 2004;22(3):181-186.
60. Currier GW, Chou JC, Feifel D, et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry. 2004;65(3):386-394.
61. van Schaick EA, Lechat P, Remmerie BM, Ko G, Lasseter KC, Mannaert E. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther. 2003;25(6):1687-1999.
62. United States Food and Drug Administration. Abilify (aripiprazole) Discmelt orally disintegrating tablets. 2008. Available at: www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm113232.htm. Accessed June 21, 2010.
63. Thyssen A, Remmerie B, D'Hoore P, Kushner S, Mannaert E. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability. Clin Ther. 2007;29(2):290-304.
64. Markowitz JS, DeVane CL, Malcolm RJ, et al. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacol. 2006;46(2):164-171.
65. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl). 2001;155(2):128-134.
66. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59(5):441-448.
67. Damsa C, Adam E, Lazignac C, et al. Intramuscular olanzapine in patients with schizophrenia: an observational study in an emergency room. Bull Soc Sci Med Grand Duche Luxemb. 2008;(2):209-216.
68. Cañas F. Management of agitation in the acute psychotic patient-efficacy without excessive sedation. Eur Neuropsychopharmacol. 2007;17(suppl 2):S108-S114.
69. Centorrino F, Meyers AL, Ahl J, et al. An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder. Hum Psychopharmacol. 2007;22(7):455-462.
70. Battaglia J, Lindborg SR, Alaka K, Meehan K, Wright P. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med. 2003;21(3):192-198.
71. Boomsma MM, Mengels O, van Olden RW. Risks associated with parenteral treatment of acute agitation. Tijdschr Psychiatr. 2006;48(2):135-139.
72. Viejo LF, Morales V, Puñal P, Pérez JL, Sancho RA. Risk factors in neuroleptic malignant syndrome. A case-control study. Acta Psychiatr Scand. 2003;107(1):45-49.
73. Bellnier TJ. Continuum of care: stabilizing the acutely agitated patient. Am J Health Syst Pharm. 2002;59(suppl 5):S12-S18.
74. Currier GW, Trenton A. Pharmacological treatment of psychotic agitation. CNS Drugs. 2002;16(4):219-228.
75. Hovens JE, Dries PJ, Melman CT, Wapenaar RJ, Loonen AJ. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study. J Psychopharmacol. 2005;19(1):51-57.
76. Currier GW, Trenton AJ, Walsh PG, van Wijngaarden E. A pilot, open-label safety study of quetiapine for treatment of moderate psychotic agitation in the emergency setting. J Psychiatr Pract. 2006;12(4):223-228.
77. Daniel DG, Currier GW, Zimbroff DL, et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. J Psychiatr Pract. 2007;13(3):170-177.
78. Hoyumpa AM Jr. Alcohol interactions with benzodiazepines and cocaine. Adv Alcohol Subst Abuse. 1984;3(4):21-34.
79. Sharif ZA. Pharmacokinetics, metabolism, and drug-drug interactions of atypical antipsychotics in special populations. Prim Care Companion J Clin Psychiatry. 2003;5(suppl 6):22-25.
80. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100(1):4-22.
81. Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract. 2009;63(2):1762-1784.
82. Nordstrom K. Inhaled loxapine for acute agitation in schizophrenia and bipolar disorder. Future Neurol. 2009;4(5):539-545.